We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




How Regulators of Fat Metabolism Work

By Biotechdaily staff writers
Posted on 25 Jul 2002
The hormone leptin has been found to specifically repress RNA levels and enzymatic activity of a gene that catalyzes the biosynthesis of monounsaturated fatty acids, causing fat to be metabolized for energy rather than being stored. More...
This finding and others were contained in an article published in the July 12, 2002, issue of Science.

Researchers at Rockefeller University (New York, NY, USA) found that when they crossed obese (ob/ob) mice that lack leptin with a strain called "asebia,” which carries mutations in the SCD-1 gene, the obese mice lost weight despite continuing to overeat. Leptin caused weight loss by reducing food intake and by increasing energy expenditure, while a deficiency of SCD-1 reduced obesity by increasing energy expenditure without affecting food intake at all.

Similar to leptin treatment, removal of SCD-1 markedly reduced the weight of the obese mice. At 16 weeks of age, weight was reduced by 29% in females and 34% in males. The reduced weight of these animals could be accounted for by a dramatic increase in energy expenditure. Removing SCD-1 completely corrected the effects of leptin deficiency on energy expenditure.

"The repression of SCD-1 accounts for a significant proportion, perhaps even all, of the effects of leptin on energy expenditure, explained Dr. Jeffrey Friedman of the laboratory of molecular genetics. "SCD-1 may act like a switch to control fat storage. When SCD-1 is ‘up,' the switch is flipped in the direction of storing fat, and when it's ‘down,' the switch is flipped in the direction of burning fat.”

Obese (leptin-deficient) mice also have massively fatty livers, which is corrected when the mice are given leptin. The lack of SCD-1 in the mutant mice also caused their livers to be normal and not fatty. "Inhibiting SCD-1 could be of potential use for reducing weight and for reducing fat content in liver, which is also an important clinical problem,” said Dr. Friedman. "Still, many more studies will be necessary to confirm that molecules that inhibit SCD-1 have an acceptable therapeutic index.”

In the current study investigators used DNA microarrays. These were evaluated with the help of a computer program that was able to sift through some 6,500 mouse genes contained in a single gene chip. The researchers sought genes that were specifically suppressed by leptin, and SCD-1 topped a final list of 36 genes.



Related Links:
Rockefeller University

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Pipette Calibration System
Artel PCS®
New
Microbiology Laboratory Automation Solution
BD Kiestra™ ReadA+BarcodA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.